Improving preparedness for introducing and scaling up long-acting HIV pre-exposure prophylaxis in Asia.
Sex Health
; 212024 Jun.
Article
in En
| MEDLINE
| ID: mdl-38833542
ABSTRACT
Long-acting injectable PrEP, particularly cabotegravir (CAB-LA), has the potential to enhance HIV prevention in Asia, and was the topic of a roundtable held in Singapore in June 2023. Despite proven efficacy, CAB-LA's impact in Asia is hindered by regulatory, manufacturing, and cost barriers. There is an urgent need to address these challenges to expedite CAB-LA's introduction and scale-up, including collaborative research, streamlined regulatory processes, and increased manufacturing capacity. We call for better preparedness in long-acting PrEP in research and implementation science, product licensing and accessibility, and capacity readiness for scale-up, to meet the significant demand among key populations in Asia.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
HIV Infections
/
Anti-HIV Agents
/
Pre-Exposure Prophylaxis
Limits:
Humans
Country/Region as subject:
Asia
Language:
En
Journal:
Sex Health
Journal subject:
DOENCAS SEXUALMENTE TRANSMISSIVEIS
Year:
2024
Document type:
Article
Affiliation country:
Country of publication: